Cleveland BioLabs and Incuron Announce Poster Presentation at 2013 European Cancer Congress

Cleveland BioLabs and Incuron Announce Poster Presentation at 2013 European
Cancer Congress

BUFFALO, N.Y., Sept. 19, 2013 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc.
(Nasdaq:CBLI) and Incuron, LLC, a joint venture between CBLI and Bioprocess
Capital Ventures today announced a poster presentation at the 2013 European
Cancer Congress, September 27- October 1, 2013 in Amsterdam, Netherlands.

Katerina Gurova, MD, Ph.D., Assistant Professor of Oncology, Department of
Cell Stress Biology, Roswell Park Cancer Institute, will present a poster
titled, "Facilitates chromatin transcription (FACT) complex as a marker and
target of aggressive poorly differentiated cancers," on September 28, which
describes FACT as an attractive target and marker of poorly differentiated
aggressive cancers based on its role as an accelerator of oncogenic
transformation through selective chromatin remodeling of genes involved in
cancer stress response and maintenance of pluripotent cell state.

FACT is the molecular target of CBL0137, a drug in development by Incuron. The
first patient was recently dosed in a multi-center Phase 1 trial evaluating
intravenous administration of CBL0137 in patients with metastatic or
unresectable advanced solid cancers and lymphomas in the U.S. An ongoing Phase
1 study of oral administration of CBL0137 in patients with advanced solid
tumors that are resistant or refractory to standard of care treatment is being
conducted in the Russian Federation.

For more information about the European Cancer Congress, please refer to:

About Cleveland BioLabs, Inc.

Cleveland BioLabs, Inc. is a clinical-stage biotechnology company leveraging
deep mechanistic understanding of the cell death process, apoptosis, to
develop a robust pipeline of compounds primarily focused on oncology
applications and mitigation of radiation injury. The Company's lead compound
is being developed as both a radiation countermeasure and a cancer treatment.
The Company has two operating subsidiaries, Incuron, LLC, and Panacela Labs,
Inc., and strategic relationships with the Cleveland Clinic, Roswell Park
Cancer Institute, the Children's Cancer Institute Australia and the Armed
Forces Radiobiology Research Institute. To learn more about Cleveland BioLabs,
Inc., please visit the Company's website at

About Incuron, LLC

Incuron, LLC is a Russian Federation based joint venture founded in 2010
between Russian Closed Mutual Venture Fund "Bioprocess Capital Ventures," and
Cleveland BioLabs. Incuron is developing CBL0102 and CBL0137 for oncology and
orphan indications. To learn more about Incuron, LLC, please visit the
company's website at

This press release contains certain forward-looking information about
Cleveland BioLabs that is intended to be covered by the safe harbor for
"forward-looking statements" provided by the Private Securities Litigation
Reform Act of 1995, as amended. Forward-looking statements are statements that
are not historical facts. Words such as "expect(s)," "feel(s)," "believe(s),"
"will," "may," "anticipate(s)" and similar expressions are intended to
identify forward-looking statements. These statements include, but are not
limited to, statements regarding our ability to successfully develop and
commercialize our therapeutic products; the conduct and results of our various
clinical trials; and future performance. All of such statements are subject to
certain risks and uncertainties, many of which are difficult to predict and
generally beyond the control of the Company, that could cause actual results
to differ materially from those expressed in, or implied or projected by, the
forward-looking information and statements.

These factors include, among others, the Company's failure to successfully and
timely develop new products; the risks inherent in the early stages of drug
development and in conducting clinical trials; the Company's collaborative
relationships and the financial risks related thereto; the Company's ability
to comply with its obligations under license agreements; the Company's history
of operating losses and the potential for future losses, which may lead the
Company to not be able to continue as a going concern; the Company's need for
substantial additional financing to meet its business objectives; the
potential for the loss of funding from the Company's R&D grants and contracts
and its ability to win additional funding under such grants and contracts.
Some of these factors could cause future results to materially differ from the
recent results or those projected in forward-looking statements. See also the
"Risk Factors" and "Forward-Looking Statements" described in the Company's
periodic filings with the Securities and Exchange Commission.

Rachel Levine, Vice President, Investor Relations
Cleveland BioLabs, Inc.
T: (646) 284-9439

Cleveland BioLabs, Inc. Logo
Press spacebar to pause and continue. Press esc to stop.